Daniel Bradbury Sells 7,867 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.44, for a total value of $231,604.48. Following the sale, the director now directly owns 5,700 shares of the company’s stock, valued at approximately $167,808. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Daniel Bradbury also recently made the following trade(s):

• On Monday, August 12th, Daniel Bradbury sold 7,883 shares of Castle Biosciences stock. The stock was sold at an average price of $26.65, for a total value of $210,081.95.

Castle Biosciences Stock Down 1.6 %

CSTL opened at $28.30 on Friday. The firm has a market cap of $781.28 million, a P/E ratio of -24.55 and a beta of 1.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. The business has a 50 day moving average price of $28.46 and a 200 day moving average price of $24.06. Castle Biosciences, Inc. has a twelve month low of $12.07 and a twelve month high of $32.53.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The business had revenue of $87.00 million during the quarter, compared to analysts’ expectations of $69.95 million. During the same period in the previous year, the company earned ($0.70) earnings per share. Research analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Institutional Investors Weigh In On Castle Biosciences

A number of hedge funds have recently bought and sold shares of CSTL. RiverPark Advisors LLC lifted its position in shares of Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after purchasing an additional 2,242 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Castle Biosciences by 70.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock valued at $117,000 after acquiring an additional 2,187 shares during the period. Denali Advisors LLC acquired a new stake in shares of Castle Biosciences in the first quarter worth $186,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Castle Biosciences by 10.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after acquiring an additional 952 shares during the period. Finally, Birchview Capital LP acquired a new position in Castle Biosciences during the 4th quarter valued at $216,000. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Stephens restated an “overweight” rating and issued a $37.00 price objective on shares of Castle Biosciences in a report on Tuesday, August 6th. Robert W. Baird increased their price target on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences has a consensus rating of “Buy” and an average price target of $32.80.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.